Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden

REFERENCES

• Boulware S, Tamborlane W, Sherwin R. Effects of IGF-I on carbohydrate and lipid metabolism. Dia-betes Rev 1995; 3: 199–205.
   Google Scholar
• Bang P, Hall K. Insulin-like growth factors as endocrine and paracrine hormones. In: Schofield P, editor The insulin-like growth factors: structures and biological function. Oxford: Oxford University Press, 1992: 151–77.
   Google Scholar
• Brismar K, Hilding A, Lindgren B. Regulation of IGFBP-1 in humans. Progr Growth Factor Res 1995; 6: 449–56.
   PubMedGoogle Scholar
• Baxter R, Martin J, Beniac V. High molecular weight insulin-like growth factor binding protein complex. J Biol Chem 1989; 264: 11842–8.
   Google Scholar
• Cohen P, Fielder P, Hasegawa Y, Frisch H, Guidice L, Rosenfeld R. Clinical aspects of insulin-like growth factor binding proteins. Acta Endocrinol (Copenh) 1991; 124: 74–85.
   PubMedGoogle Scholar
• Brismar K, Hall K. Clinical application if IGFBP-1 and its regulation. Growth Regul 1993: 98–100.
   PubMedGoogle Scholar
• Baxter R, Cowell C. Diurnal rhythm of growth hor-mone-independent binding protein for insulin-like growth factors in human plasma. J Clin Endocrinol Metab 1987; 65: 432–40.
   PubMed Web of Science ®Google Scholar
• Hilding K, Brismar M, Degerblad M, Thorén M, Hall K. Altered relation between circulation levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab 1995; 80: 2646–52.
   Google Scholar
• Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. The effect of insulin on the hepatic secretion of IGFBP-1, IGFBP-3 and IGF-I in insulin-depen-dent diabetes. J Clin Endocrinol Metab 1994; 79: 872–8.
   PubMed Web of Science ®Google Scholar
• Lindgren B, Isaksson M, Stern I, Hall K. Insulin-like growth factor binding protein-1 from Hep G2 cells is potently inhibited by the truncated IGF-I analogue des-(1-3) IGF-I. Acta Endocrinol 1993; 128: 81–7.
   PubMedGoogle Scholar
• Powell A, Suwanchkil M, Cubbage L, Paolis D, Snuggs M, Lee P. Insulin inhibits transcription of the human gene for insulin-like growth factor bind-ing protein-1. J Biol Chem 1991: 18868–76.
   PubMedGoogle Scholar
• Fernquist-Forbes J, Wahren A, Hilding A, Brismar K. Circulating epinephrine stimulates the secretion of IGFBP-1 in humans. Abstract. Growth Regul 1994; 4 Suppl 1: 92.
   Google Scholar
• Hilding A, Brismar K, Thorén M, Hall K. Gluca-gon stimulates insulin-like growth-factor binding protein-1 secretion in healthy subjects, patients with pituitary insufficiency, and patients with insu-lin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1142–7.
   Google Scholar
• Lewitt M, Baxter R. Inhibitors of glucose uptake stimulate the production of insulin-like growth fac-tor binding protein (IGFBP-1) by human fetal liver. Endocrinology 1990; 126: 1527–33.
   PubMedGoogle Scholar
• Hall K, Lundin G, POvoa G. Serum levels of the low molecular weight form of insulin-like growth factor binding protein in healthy subjects and patients with growth hormone deficiency, acrome-galy and anorexia nervosa. Acta Endocrinol (Copenh) 1988; 118: 321–6.
   Google Scholar
• Bang P, Brismar K, Rosenfeld R, Hall K. Fasting affects serum insulin-like growth factors (IGFs) and IGF binding proteins differently in patients with NIDDM versus healthy non-obese and obese, weight-matched subjects. J Clin Endocrinol Metab 1994; 78: 960–7.
   PubMedGoogle Scholar
• Clemmons D. Insulin-like growth factor binding proteins. Trends Endocrinol Metab 1990: 412–17.
   PubMedGoogle Scholar
• Lindgren B, Odar-Cederlöf I, Ericsson F, Brismar K. Decreased bioavailability of insulin-like growth factor-I, a cause of catabolism in hemodialysis patients? Growth Regul 1996; 6: 137–43.
   PubMedGoogle Scholar
• Nygren J, Sammann M, Malm M, Efendic S, Hall K, Brismar K, et al. Disturbed anabolic hormonal pattern in burned patients—the relation to gluca-gon. Clin Endocrinol 1995; 43: 491–500.
   PubMedGoogle Scholar
• Hong Y, Pedersen N, Brismar K, Hall K U, d. Faire. Quantitative genetic analyses of insulin-like growth factor I (IGF-I), IGF-binding protein-1, and insulin levels in middle-aged and elderly twins. J Clin Endocrinol Metab 1996; 81: 1791–7.
   Google Scholar
• Rajkumar K, Barron D, Lewitt M, Murphy L. Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice. Endocrinology 1995; 136: 4029–34.
   PubMed Web of Science ®Google Scholar
• Thissen J, Davenport M, Pucilowska J, Miles M, Underwood L. Increased serum clearance and degradation of 125I-labeled IGF-I in protein-restricted rats. Endocrinol Metab 1992: E408–11.
   Google Scholar
• Hall K, Johansson B, Povoa G, Thalme B. Serum levels of insulin-like growth factor (IGF)I, II and IGF binding protein in diabetic adolescents treated with continuous subcutaneous insulin infusion. J Int Med 1989; 225: 273–8.
   PubMedGoogle Scholar
• Taylor A, Dunger D, Preece M. The growth hor-mone independent insulin-like growth factor-I binding protein BP28 is associated with serum insu-lin-like growth factor-I inhibitory bioactivity in adolescent insulin-dependent diabetes. Clin Endo-crinol 1990; 32: 229–39.
   Google Scholar
• Brismar K, Gutniak M, Povoa G, Werner S, Hall K. Insulin regulates the 35 KDa IGF binding pro-tein in patients with diabetes mellitus. J Intern Med 1988; 11: 599–602.
   Google Scholar
• Gibson J, Westwood M, Crosby S, Gordon C, Holly J, Fraser W, etal. Choice of treatment affects plasma levels of insulin-like growth factor-binding protein-1 in non-insulin-dependent diabetes melli-tus. J Clin Endocrinol Metab 1995; 80: 1369–75.
   Google Scholar
• Clauson P, Linnarsson R, Gottsäter A, Sundkvist G, Grill V. Relationships between diabetes dura-tion, metabolic control and b-cell function in a representative population of type 2 diabetic patients in Sweden. Diabetes Med 1994; 11: 794–801.
   Google Scholar
• Linnarsson R. Development and evaluation of a complete computer-based problem-orientated medical record system for primary care. MIE (Medical Informatics Europe) 87 Proceedings 1987: 209–14.
   Google Scholar
• Barnett G. The application of computer-based medical record systems in ambulatory care. N Engl J Med 1984; 310: 1643–50.
   PubMedGoogle Scholar
• Webster S, Morgan M, Barnett G. Medical query language: improved access to MUMPS databases. Proceedings of the 11th Annual Symposium on Computer Application in Medical Care, Wahing-ton 1987: 306–9.
   Google Scholar
• Tridner P. Determination of glucose in blood using glucose oxidase with an alternative oxygen recep-tor. Ann Clin Biochem 1969; 6: 24–7.
   Google Scholar
• Jeppsson J, Jerntorp P, Sundkvist G, Englund H, Nylund V. Measurement of hemoglobin Alc by a new liquid-chromatographic assay: methodology, clinical utility, and relation to glucose tolerance evaluated. Clin Chem 1986; 32: 1867–72.
   Google Scholar
• v. Rijn H, Hoekstra J, Thijssen J. Evaluation of three commercially available C-peptide kits. Ann Clin Biochem 1982; 19: 368–73.
   Google Scholar
• Koskinen P. Nontransferability of C-peptide mea-surements with various commercial radioimmu-noassay reagents. Clin Chem 1988; 8: 1575–8.
   Google Scholar
• Herbert V, Lau K, Gottlieb C, Bleicher S. Coated charcoal immunoassay of insulin. J Clin Endocri-nol Metab 1965; 25: 1375–84.
   PubMed Web of Science ®Google Scholar
• Bang P, Eriksson U, Sara V, Wirall I-L, Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and and -II radioimmu-noassays: improvement of determinations in acid ethanol extractions by use of truncated IGF-I as radioligand. Acta Endocrinol 1991; 124: 620–9.
   Google Scholar
• Povoa G, Rodvete A, Hall K. Cross-reaction of serum somatomedin binding protein in a radioim-munoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol 1984; 107: 563–7.
   Google Scholar
• Alberti K, Gries F. Management of non-insulin-dependent diabetes mellitus in Europe: a consensus view. Diabetic Med 1988: 5.
   Google Scholar
• Cerasi E, Luft R. "What is inherited—what is added" hypothesis for the pathogenesis of diabetes mellitus. Diabetes 1967; 16: 615–27.
   PubMedGoogle Scholar
• DeFronzo R, Ferranini E. Insulin resistance, a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and athero-sclerotic cardiovascular disease. Diabetes Care 1991; 14: 173–94.
   PubMed Web of Science ®Google Scholar
• Cerasi E. Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Diabetologia 1995; 38: 992–7.
   PubMedGoogle Scholar
• Efendic S, Luft R, Wajngot A. Aspects of the pathogenesis of type 2 diabetes. Endocrinol Rev 1984; 5: 395–410.
   Google Scholar
• Midthjell K, Bjorndal A, Holmen J, Kruger 0, Bjartveit K. Prevalence of known and previously unknown diabetes mellitus and impaired glucose tolerance in an adult Norwegian population. Indi- cations of an increasing diabetes prevalence. The Nord-Trondelag Diabetes Study. Scand J Prim Health Care 1995; 13: 229–35.
   Google Scholar
• Eriksson J, Forsen B, Haggblom M, Teppo AM, Groop L. Clinical and metabolic characteristics of type 1 and type 2 diabetes: an epidemiological study from the Narpes community in western Fin-land. Diabetes Med 1992; 9: 654–60.
   Google Scholar
• Sartor G. Prevalence of type 2 diabetes in Sweden. Acta Endocrinol 1984; Suppl 262: 27–9.
   Google Scholar
• v. Gaal L, Vansant G, v. Acker K, d. Leeuw I. Decreased hepatic insulin extraction in upper body obesity: relationship to unbound androgens and sex hormone binding globulin. Diabetes Res Clin Pract 1991; 12: 99–106.
   PubMedGoogle Scholar
• Faloona G, Unger R. In:. Jaffe B, Behrman H, edi-tors. Glucagon. New York: Academic Press, 1974: 317–30.
   Google Scholar